Related Experiment Video
Updated: Jan 5, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Death with an implantable cardioverter-defibrillator: a MADIT-II substudy
Fernando Chernomordik1,2,3, Christian Jons4, Helmut U Klein4
1Leviev Heart Center, Sheba Medical Center, Ramat Gan, Israel.
Insights
Sudden cardiac death classification is inaccurate for implantable cardioverter-defibrillator patients. Device data and clinical factors like heart failure hospitalizations identify ventricular tachyarrhythmic mortality risk.
Area of Science:
- Cardiology
- Medical Devices
- Clinical Trials
Background:
- Limited data exist on factors predicting ventricular tachyarrhythmic (VTA) or non-arrhythmic (NA) mortality in implantable cardioverter-defibrillator (ICD) patients.
- Current sudden cardiac death (SCD) vs. non-sudden cardiac death (NSCD) classification may lack accuracy.
Purpose of the Study:
- To correlate clinical adjudication of mortality events with device interrogation data in MADIT-II.
- To identify risk factors for VTA mortality in ICD recipients.
Main Methods:
- Analysis of 746 ICD patients from the MADIT-II trial with available interrogation data at death.
- Categorization of deaths into VTA or NA based on device interrogation, validating clinical adjudication.
- Multivariate analysis to identify independent risk factors for VTA mortality.
Main Results:
- Clinical adjudication of SCD/NSCD was inaccurate; 50% of adjudicated SCD and 25% of adjudicated NSCD events were misclassified regarding VTA.
- Factors independently associated with VTA mortality included prior VT/VF, heart failure hospitalization, and hypertension.
- Hazard ratios for VTA mortality were 8.0 for prior VT/VF, 6.7 for heart failure hospitalization, and 4.0 for hypertension.
Conclusions:
- The current SCD vs. NSCD classification is insufficient for accurately identifying VTA events in ICD recipients.
- Simple clinical parameters can identify ICD patients at increased risk for VTA mortality.
Aims:
There are limited data regarding factors that identify implantable cardioverter-defibrillator (ICD) patients who will experience either ventricular tachyarrhythmic (VTA) or non-arrhythmic (NA) mortality, and the commonly used clinical classification of sudden cardiac death (SCD) vs. non-sudden cardiac death (NSCD) may not be accurate enough. We aimed to correlate clinical adjudication of mortality events to device interrogation data and to identify risk factors for VTA mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
Methods And Results:
Of the 746 patients who received an ICD in MADIT-II, 44 died from cardiac causes and had available interrogation data at the time of death. Sudden cardiac death vs. NSCD was defined by an adjudication committee. Ventricular tachyarrhythmic and NA arrhythmic deaths were categorized by the presence or absence of ventricular tachycardia or fibrillation (VT/VF) during the terminal event. Mode of death was found to be inaccurate when validated by device interrogation for VTA events: 50% patients adjudicated as SCD did not have a VTA event at the time of death; and 25% of adjudicated NSCD were found to have VT/VF during the mortality event. Multivariate analysis showed that factors independently associated with VTA mortality included: VT/VF >72 h prior to the mortality event [hazard ratio (HR) 8.0; P < 0.001], hospitalization for heart failure (HR 6.7; P = 0.001), and a history of hypertension (HR 4; P = 0.04).
Conclusion:
Current classification of SCD vs. NSCD fails to identify VTA events at the time of death in a significant proportion of patients, and simple clinical parameters can be used to identify ICD recipients with increased risk for VTA mortality.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiopulmonary Resuscitation III: AED Use
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy

